NR1I2 and acute kidney injury: Dou et al. [57] firstly identified the nuclear receptor family as a new target for cisplatin-induced AKI by network pharmacology, and further in vitro and in vivo studies revealed that Tan IIA could reduce renal inflammation and pathological damage by inhibiting the pregnane X receptor (PXR)-mediated NF-κB signaling pathway through activating PXR.